Beta-Amyloid-Dependent Mirnas As Circulating Biomarkers in Alzheimer’S Disease: A Preliminary Report Publisher Pubmed



Hajjri SN^{1, 2} ; Sadigheteghad S² ; Mehrpour M³ ; Moradi F⁴ ; Shanehbandi D⁵ ; Mehdizadeh M⁶ Show Affiliations
Source: Journal of Molecular Neuroscience Published:2020

Abstract

MicroRNAs (miRNAs) are considered among the most reliable biomarkers to diagnose and predict Alzheimer’s disease (AD), due to their regulatory nature. The main goal of this study was to evaluate the expression of miR4422 and miR3714, as the main regulators of GSAP and BACE1 expression, in AD patients compared with healthy subjects. Twenty patients with a mild to moderate AD (58–71 years old) and 15 healthy subjects (58–73 years old) participated in this study. The expression levels of miR4422 and miR3714 as the target genes and 5S rRNA and miRlet7a-5p as the reference genes were measured in the two groups. To compare the expression between the case and the control groups, the t test or the Wilcoxon test was used, based on the data distribution patterns. The efficiencies of amplification of the miR4422, miR3714, 5S rRNA, and miRlet7a-5p genes all were in the acceptable range. The mean miR4422-5S rRNA dCt value was significantly different between the two groups (p = 0.018). The relative fold change of the expression was 0.43. The mean miR4422-miRlet7a-5p dCt value (p = 0.41), the mean miR3714-5S rRNA dCt value (p = 0.10), and the mean miR3714-miRlet7a-5p dCt value (p = 0.063) were not significantly different between the two groups. We indicated that miR4422 could be a reliable biomarker for Alzheimer’s diagnosis. It seems that the reduced expression of miR4422 that targets GSAP and BACE1 expression can lead to an increase in the formation of Aβ plaque. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.